Key terms
About DYN
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DYN news
Today
5:10am ET
Analysts Conflicted on These Healthcare Names: Dyne Therapeutics (DYN) and Geron (GERN)
Today
5:01am ET
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)
Mar 26
8:00am ET
Analysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)
Mar 25
7:52am ET
Dyne Therapeutics Welcomes John Cox as New CEO and Board Member
Mar 25
7:47am ET
Dyne Therapeutics CEO Joshua Brumm to step down, John Cox to succeed
Mar 08
4:24am ET
Dyne Therapeutics price target raised to $31 from $20 at Chardan
Mar 07
11:25pm ET
Buy Rating Affirmed for Dyne Therapeutics: Promising Clinical Data and Solid Financial Position Fuel Optimism
Mar 06
11:45am ET
Buy Rating Affirmed for Dyne Therapeutics Amidst Promising Drug Data and Strategic Market Positioning
Mar 06
11:33am ET
Dyne Therapeutics price target raised to $37 from $33 at Guggenheim
Mar 06
7:36am ET
Piper Sandler Keeps Their Buy Rating on Dyne Therapeutics (DYN)
Mar 06
7:21am ET
Dyne Therapeutics price target raised to $29 from $27 at Piper Sandler
Mar 06
7:19am ET
Dyne Therapeutics price target raised to $41 from $35 at Stifel
Mar 06
6:37am ET
Dyne Therapeutics: Strong Buy on Promising Clinical Data and Superior Therapeutic Platform
Mar 05
8:25am ET
Dyne Therapeutics files automatic mixed securities shelf
Mar 05
7:42am ET
Dyne Therapeutics price target raised to $47 from $44 at Oppenheimer
Mar 05
7:42am ET
Dyne Therapeutics reports Q4 EPS ($1.09), consensus (92c)
Feb 20
6:07am ET
Dyne Therapeutics initiated with a Buy at H.C. Wainwright
Feb 09
8:29am ET
Stifel Nicolaus Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
Jan 31
1:00am ET
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Silence Therapeutics (SLN) and Dyne Therapeutics (DYN)
No recent press releases are available for DYN
DYN Financials
Key terms
Ad Feedback
DYN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DYN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
